Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - fentanyl citrate, quantity: 392.5 microgram (equivalent: fentanyl, qty 250 microgram) - injection, solution - excipient ingredients: sodium chloride; water for injections - analgesic action of short duration during anaesthetic periods, premedication, induction and maintenance, and in the immediate post-operative period (recovery room) as the need arises - use as an opioid analgesic supplement in general and regional anaesthesia - administration with a neuroleptic such as droperidol injection as an anaesthetic premedication, for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - fentanyl citrate, quantity: 157 microgram (equivalent: fentanyl, qty 100 microgram) - injection, solution - excipient ingredients: sodium chloride; water for injections - analgesic action of short duration during anaesthetic periods, premedication, induction and maintenance, and in the immediate post-operative period (recovery room) as the need arises - use as an opioid analgesic supplement in general and regional anaesthesia - administration with a neuroleptic such as droperidol injection as an anaesthetic premedication, for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 314 microgram (equivalent: fentanyl, qty 200 microgram) - tablet, orally disintegrating - excipient ingredients: magnesium stearate; sodium bicarbonate; mannitol; citric acid; sodium starch glycollate type a; sodium carbonate - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 1.257 mg (equivalent: fentanyl, qty 800 microgram) - tablet, orally disintegrating - excipient ingredients: magnesium stearate; citric acid; sodium carbonate; sodium bicarbonate; sodium starch glycollate type a; mannitol - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 157 microgram (equivalent: fentanyl, qty 100 microgram) - tablet, orally disintegrating - excipient ingredients: mannitol; sodium carbonate; sodium bicarbonate; citric acid; sodium starch glycollate type a; magnesium stearate - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 943 microgram (equivalent: fentanyl, qty 600 microgram) - tablet, orally disintegrating - excipient ingredients: sodium bicarbonate; magnesium stearate; sodium carbonate; sodium starch glycollate type a; citric acid; mannitol - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 628 microgram (equivalent: fentanyl, qty 400 microgram) - tablet, orally disintegrating - excipient ingredients: magnesium stearate; sodium carbonate; sodium starch glycollate type a; sodium bicarbonate; citric acid; mannitol - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Canada - English - Health Canada

david bull laboratories (canada) inc. - fentanyl (fentanyl citrate) - liquid - 50mcg - fentanyl (fentanyl citrate) 50mcg - opiate agonists

Canada - English - Health Canada

hospira healthcare ulc - fentanyl (fentanyl citrate) - solution - 50mcg - fentanyl (fentanyl citrate) 50mcg - opiate agonists

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 1.28 mg in 1 [usp'u] - fentanyl transdermal system is indicated for management of persistent , moderate to severe chronic pain that: - requires continuous, around-the-clock opioid administration for an extended period of time, and - cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids fentanyl transdermal system should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system 25 mcg/hr (see dosage and administration). patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. because serious or life-threatening hypoventilation could result, fentanyl transdermal system is contraindicated for use on an as needed basis (i.e., prn